HA disruption with the PEGylated human recombinant PH20 hyaluronidase (PEGPH20) indicated improved drug delivery and response in a mouse model of pancreatic cancer and increased CD8+ T cell infiltration and better checkpoint inhibitor efficacy in a syngeneic breast cancer mouse model [54,55]. This evidence concerns the gene CD8A and breast carcinoma.